logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Positive News for Two Undervalued Firms in the Prohost Portfolio

Exelixis CABOMETYX Approval Exelixis ( EXEL ) partner Ipsen received approval from the European Commission ( EC ) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma ( DTC ), which is...

Read More

May 5, 2022

0

TG Therapeutics Launched FDA Approved Product  BRIUMVI™ for Patients with Relapsing Forms of MS

TG Therapeutics  TG Therapeutics ( TGTX ) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for B-cell diseases. The firm’s research pipeline has several investigational medicines. TG Therapeutics has been granted U.S. FDA approval of its product BRIUMVI™...

Read More

January 27, 2023

0

Exelixis First Quarter 2022 Financial Results. See Also: Milestones in Clinical and Pipeline Development

Exelixis Press Release This press release covers a large part of Exelixis accomplishments, including important details about its pipeline products, especially, cabozantinib, in addition to new results from clinical trials. We advise Prohost subscribers to read this press release, so...

Read More

May 19, 2022

0

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

CytomX Therapeutics  We posted several articles that brought good news from CytomX Therapeutics ( CTMX ) , yet the stock continues to go down instead of up.  A few days ago, CytomX announced the achievement of a clinical candidate milestone...

Read More

February 2, 2023

0

Regeneron and Sanofi: FDA Approves Dupixent® as First Treatment for Eosinophilic Esophagitis

Regeneron Pharmaceuticals and Sanofi Announce FDA Approval of Dupixent ® Regeneron Pharmaceuticals ( REGN ) and  Sanofi ( SNY ) announced that the U.S. FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis ( EoE ) aged...

Read More

May 23, 2022

0

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals Alnylam Pharmaceuticals ( ALNY ) led the translation of RNA interference ( RNAi ) into a new class of innovative therapeutics, transforming the lives of people afflicted with rare and prevalent diseases with unmet needs. RNAi is a...

Read More

May 25, 2022

0

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. Investors in the biotech sector who intend to bet on clinical stage firms must restrict their choices to companies that already have proof of...

Read More

February 13, 2023

0

The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

United Therapeutics Approval for Tyvaso DPI™ The US FDA approved United Therapeutics ( UTHR ) product Tyvaso DPI™ (treprostinil) inhalation powder for pulmonary arterial hypertension ( PAH ) and pulmonary hypertension associated with interstitial lung disease ( ILD ) to...

Read More

May 27, 2022

0

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. ( APLS ) is a biopharma firm developing novel products for debilitating and life-threatening diseases. Currently, Apellis has two approved medicines targeting C3. These drugs include the first and only approved therapy for geographic atrophy,...

Read More

February 23, 2023

0

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb ( BMY ) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients with moderate to severe systemic lupus erythematosus ( SLE ). The study met...

Read More

June 2, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 39
  • 40
  • 41
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy